Apexigen develops antibody therapeutics for oncology using its proprietary APXiMAB discovery platform. Its lead program, APX005M, is a monoclonal antibody targeting CD40 and is in multiple Phase 2 clinical trials for various solid tumors. The company plans to use proceeds to support ongoing clinical development of APX005M and to advance at least one new proprietary immunotherapeutic into Phase 1. Apexigen and its licensees have seven products or product candidates discovered via APXiMAB that are commercially available or in clinical development. The company is led by President and CEO Xiaodong Yang and is based in San Carlos, California. Financially, the company has raised $158M in total equity to date following the recent Series C extension. Apexigen is a San Carlos, Calif.-based clinical-stage biopharmaceutical company led by Xiaodong Yang, M.D., Ph.D. The company develops a new generation of antibody therapeutics for oncology, with an emphasis on immuno-oncology agents. Its lead program, APX005M, is a novel humanized monoclonal antibody that targets CD40 and stimulates anti-tumor immune responses. Binding of APX005M to CD40 on antigen-presenting cells (dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response involving T cells and macrophages. APX005M is in multiple Phase 2 clinical trials for indications including melanoma, non-small cell lung cancer, pancreatic cancer and renal cell carcinoma in various combinations with immunotherapy, chemotherapy or radiation therapy. The company intends to use recent financing proceeds to advance clinical development of APX005M and to discover and develop its broader pipeline of therapies. Apexigen is a Burlingame, Calif.-based biopharmaceutical product development company founded in 2010 and led by President & CEO Xiaodong Yang, MD, PhD. The company is advancing a pipeline of humanized antibodies targeting cancer, inflammatory diseases and ophthalmic disease. Its lead program is APX005, a CD40 agonist immunotherapeutic that stimulates anti-tumor immune responses by binding CD40 on antigen-presenting cells, activating co-stimulatory pathways, and can also trigger direct tumor killing. Apexigen closed a $20m Series A1 financing to fund development. The company intends to use the funds to advance APX005 and to support the development of additional pipeline programs. In conjunction with the funding, Dr. George J. Lee of Amkey Ventures joined Apexigen’s board of directors.

Total raised

$158M

Funding rounds

4

Latest round

Series C

Latest activity

Mar 2020